Ooocx

Restriction enzymes, 4:31-34 as biotechnology tool, 1:70-71,

2:107, 3:114, 4:33-34 in blotting procedures, 1:88 defined, 1:70, 2:49, 3:152, 4:5 as DNA fingerprinting tool, 4:32, 4:33-34

DNA methylation role, 3:47, 4:31 in DNA sequencing, 4:70 in electrophoresis, 2:49 function, 3:114, 4:31 as gene cloning tool, 1:152,

1:154, 1:155, 1:157 as gene mapping tool, 4:33 nomenclature and classification, 4:31

recombinant DNA tools, 4:5-6,

4:31, 4:33 restriction maps, 1:155 RFLPs detected by, 3:13,

3:161-162, 4:34 Type I, 4:31 Type II, 4:31-32 Type III, 4:31 in VNTR analysis, 1:236 Restriction fragment length polymorphisms (RFLPs), 1:236, 3:6, 3:13-14, 3:161-162, 3:161, 4:34 Restriction maps (genes), 1:155-156, 1:156

Restriction point, in cell cycle,

1:104-105 Reticular dystenesis, 4:76 Reticuloendotheliosis virus strain T,

4:35 Retinas cherry-red spot, 4:98, 4:100 defined, 4:98 function, 1:170 Retinoblastoma gene (Rb), mutations, 1:96-97, 1:96, 3:130, 4:153 Retinoblastoma protein (pRb), phos-

phorylation, 1:106-107, 1:106 Retinoblastomas chromosome deletion role, 4:155 genetic testing, 2:100-101 mutation rates, 3:99 PML body mutations, 3:124 two-hit theory, 3:131, 4:153 Retinoic acid concentration, 2:164 influence on gene expression,

2:161, 2:162, 2:163, 2:164 risk during pregnancy, 1:206 9-cis-retinoic acid receptor (RXR) function, 2:163 nuclear receptor partners for, 2:160

Retinoic acid receptor (RAR), function, 2:163 Retroposition, gene evolution role,

2:28, 2:28, 2:30 Retroposons, 3:211-212 Retropseudogenes (processed pseudogenes), 3:210, 3:211-212, 4:8, 4:10 Retrotransposons defined, 4:143 ingi, 4:145

4:145, 4:147-148 LTRs, 4:8, 4:9-10, 4:11, 4:144, 4:145

4:144, 4:145 SINEs, 4:8, 4:10, 4:11, 4:144, 4:145, 4:147-148 Retroviridae. See Retroviruses Retroviruses (RNA viruses), 4:34-39 acutely transforming, 4:170 antiretroviral therapy, 4:41, 4:41 cancer and, 4:38-39, 4:52, 4:169 characteristics, 2:117, 4:34-35,

4:168 defined, 2:151 discovery, 4:39 endogenous, 4:35, 4:41 ex vivo gene transfer tools, 2:76 gag gene, 4:35, 4:36, 4:144, 4:145 HIV as, 2:151, 4:34, 4:40-41, 4:52 list of, 4:35

pol gene, 4:35, 4:36, 4:144, 4:145 proto-oncogene activation, 3:127 provirus (proviral DNA), 4:35-37 retrovirus-like elements, 4:41 reverse transcriptase, 4:35-37,

4:39-42 Rous sarcoma virus, 1:99-100,

4:39, 4:169 simian sarcoma (SSV), 3:130 Ty elements, 4:145 as vectors, 2:76, 4:182 Retroviruses, infection process assembly, 4:37-38, 4:37 attachment, 4:36, 4:37 cytopathic infections, 4:38 egress (release), 4:37, 4:38 infection outcomes, 4:169 latent infections, 4:38, 4:169 maturation, 4:37, 4:38 penetration, 4:36, 4:37 slowly transforming, 4:170 uncoating, 4:36, 4:37 Retrovirus-like elements, 4:41 Rett syndrome clinical features, 2:202

MeCP2 protein, 3:48, 3:49, 3:78 Rev proteins, HIV-produced, 2:153 Reverse transcriptase. See Transcrip-

tase, reverse Reverse transcriptase inhibitors,

4:41, 4:41 Reversed-phase columns, 2:166-167, 2:166

RFLPs. See Restriction fragment length polymorphisms Rh blood group discovery, 1:84 genetics of, 1:85-86 as identification, 1:233 incompatibility, 1:75, 1:84-86 Rhabdovirus (rabies virus), structure,

4:165, 4:170, 4:171 Rhinovirus, characteristics, 4:165 Rhodopsin

RHO genes, 1:171 signal transduction role, 4:89 Ribonuclease enzymes defined, 4:16

4:57-58 RNase H, 4:16 tertiary structure, 3:201 Ribonucleic acid. See RNA Ribonucleoprotein (RNA-protein)

complexes, 4:42 Ribose sugars discovery, 1:249 evolution of, 2:23 in RNA, 4:47, 4:49 structure and function, 3:115 Ribosomes, 1:105, 4:42-44, 4:43 defined, 1:29, 2:13, 4:46 eukaryotic, 4:42-43 function, 1:112, 2:62, 3:70-71,

4:43-44, 4:50, 4:136, 4:137 impact of antibiotics on, 1:28, 4:44

in mitochondria and chloroplasts, 4:42

in nucleus, 3:119, 3:125 prokaryotic, 2:16, 4:42-43 structure, 4:42, 4:51, 4:136,

4:137-138 synthesis, 4:42-43 in vivo assembly pathway, 4:43 See also RNA, ribosomal; Translation Ribozymes, 4:44-46 defined, 2:79, 4:163 discovery, 4:44 evolutionary origin, 4:46 as gene therapy tool, 2:79, 4:46 RNase P, 4:45, 4:46

0 0

Post a comment